ong Term Administration of Inhaled Mannitol in Cystic Fibrosis - A Safety and Efficacy Study
- Conditions
- mucoviscidosis1003868610010613
- Registration Number
- NL-OMON32987
- Lead Sponsor
- Pharmaxis Pharmaceuticals Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 45
1. Have given written informed consent to participate in this study in accordance with local regulations
2. Have a confirmed diagnosis of cystic fibrosis (positive sweat chloride value >= 60 mEq/L) and/or genotype with two identifiable mutations consistent with CF, accompanied by one or more clinical features consistent with the CF phenotype)
3. Be aged > 6 years old
4. Have FEV1 >40 % and < 90% predicted (using Wang <8 years and NHanes III >8years)
5. Be able to perform all the techniques necessary to measure lung function
1. Be investigators, site personnel directly affiliated with this study, or their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biologically or legally adopted.
2. Be considered *terminally ill* or eligible for lung transplantation
3. Have had a lung transplant
4. Be using nebulized hypertonic saline in the 4 weeks prior to visit 1
5. Have had a significant episode of hemoptysis (>60 mL) in the three months prior to enrolment
6. Have had a myocardial infarction in the three months prior to enrolment
7. Have had a cerebral vascular accident in the three months prior to enrolment
8. Have had major ocular surgery in the three months prior to enrolment
9. Have had major abdominal, chest or brain surgery in the three months prior to enrolment
10. Have a known cerebral, aortic or abdominal aneurysm
11. Be breast feeding or pregnant, or plan to become pregnant while in the study
12. Be using an unreliable form of contraception (female subjects at risk of pregnancy only)
13. Be participating in another investigative drug study, parallel to, or within 4 weeks of visit 0
14. Have a known allergy to mannitol
15. Be using beta blockers
16. Have uncontrolled hypertension -e.g. for adults: systolic BP > 190 and / or diastolic BP > 100
17. Have a condition or be in a situation which in the Investigator*s opinion may put the subject at significant risk, may confound results or may interfere significantly with the patient*s participation in the study
18. Be *MTT positive or incomplete*. (As evaluated in section 3.3.8.5)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Change in absolute FEV1 </p><br>
- Secondary Outcome Measures
Name Time Method